Emergent BioSolutions Announces Presentation on Bispecific Protein Therapeutic at 24th Annual EORTC-NCI-AACR Symposium

Emergent BioSolutions Inc.Robert G. Burrows, 301-795-1877Vice President, Investor RelationsorTracey Schmitt, 301-795-1800Vice President, Corporate Communications

announced today that an abstract on its bispecific protein therapeutic targeting prostate cancer has been accepted for presentation at the 24 Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 6-9, 2012 in Dublin, Ireland.

The preclinical results showed Emergent’s SCORPION (multi-specific protein therapeutic) molecules targeting prostate-specific membrane antigen (PSMA) and CD3 redirected T-cell cytotoxicity against PSMA-positive tumor cells and show potential for further investigation as possible therapeutic agents for treating castrate-resistant prostate cancer. T-cell engaging bispecific molecules linking anti-PSMA and anti-CD3 binding domains in the context of novel SCORPION proteins were evaluated both and for function and stability.

Prostate cancer is the most common cancer in men. Although screening, radiation, surgery and hormone ablation therapy have greatly improved the detection and treatment of early stage prostate cancer, few options exist to treat metastatic, castrate-resistant prostate cancer. Bispecific antibody fragments that can simultaneously engage T cells and tumor cells have been shown to destroy tumor cells by redirecting the cytotoxic function of T cells.

Emergent BioSolutions is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information about us may be found at .

Follow us on twitter: .

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.